feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

trending

Salesforce lays off 1000

trending

India US trade tariffs slashed

trending

Margot Robbie's Wuthering Heights panned

trending

CBSE board exams: key details

trending

Jana Nayagan movie court case

trending

Dhakshineswar Suresh Davis Cup hero

trending

Deepika Padukone wears Gaurav Gupta

trending

NZ vs UAE match prediction

trending

iPhone 17 Croma Valentine's sale

Home / Health / Diabetes Drug Saves Thousands: New Hope for Patients

Diabetes Drug Saves Thousands: New Hope for Patients

10 Feb

•

Summary

  • New diabetes drug reduces premature deaths by 24%.
  • Study suggests 20,000 deaths could be prevented annually.
  • Drugs protect heart and kidneys alongside blood sugar control.
Diabetes Drug Saves Thousands: New Hope for Patients

A new class of SGLT-2 inhibitor medications for type 2 diabetes has demonstrated remarkable effectiveness, potentially preventing approximately 20,000 deaths each year in the UK. Research analyzed data from 60,000 individuals, revealing a 24% decrease in premature mortality over three years compared to other treatments.

These once-daily tablets, including canagliflozin and others, work by aiding the kidneys in glucose removal. This mechanism not only lowers blood sugar but also offers significant protection to the heart and kidneys, according to emerging evidence.

The National Institute for Health and Care Excellence (Nice) has endorsed these SGLT-2 inhibitors as a first-line treatment. This recommendation, supported by UCL and LSHTM experts, signifies a substantial evolution in diabetes management affecting millions across the UK.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
SGLT-2 inhibitors reduce blood sugar by helping kidneys remove glucose through urine, and they have been shown to decrease premature deaths by 24%.
Researchers suggest that approximately 20,000 deaths could be prevented each year in the UK due to the effectiveness of these new diabetes medications.
Nice has endorsed SGLT-2 inhibitors as a first-line treatment option for type 2 diabetes, marking a significant change in patient care.

Read more news on

Healthside-arrow

You may also like

Novo Nordisk Launches Oral Ozempic in Q2

5 Feb • 45 reads

article image

AstraZeneca India Gets Green Light for New Cancer Treatment

31 Jan • 68 reads

article image

Fake Ozempic Risks: Health Canada Issues Warning

22 Jan • 117 reads

Ozempic Alters US Grocery Carts: Study Reveals Shift

31 Dec, 2025 • 186 reads

article image

FDA Approves Oral Wegovy: Game Changer for Dieters?

23 Dec, 2025 • 330 reads

article image